In-depth: New licenses could spark manufacture of COVID-19 pills in Africa
Pharmaceutical companies Merck and Pfizer recently announced early results from clinical trials showing that two new antiviral medicines are highly effective in reducing COVID-19 deaths and hospitalisation. The Medicines Patent Pool then announced licensing deals with both companies that will allow for generic versions of the two drugs to be produced. Catherine Tomlinson unpacks the licenses and asks whether generic versions of these pills might now be made in Africa.
